Effect of Vitamin D Supplementation on Graves' Disease: The DAGMAR Trial
Thyroid® · 2023
DOI: 10.1089/thy.2023.0111 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Thyroid®, 2023. Verfasst von Diana Grove-Laugesen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus N, Denmark. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Graves Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objective
Treatment options in Graves' disease (GD) are limited and do not target the underlying autoimmunity, and relapse rates following a course of antithyroid drug (ATD) reach 50%. Previous research has shown promising results for a role of vitamin D in GD. We aimed to investigate whether vitamin D reduces failure to enter and sustain remission in patients with GD treated with ATD.
Design
A multicenter, double-blinded, randomized placebo-controlled trial comparing vitamin D 70 mcg once daily (2800 IU) or placebo. The intervention was given first as add-on to ATD treatment, maximally 24 months, and then for 12 months after ATD cessation. Inclusion period was from 2015 to 2017 and study completion by December 2020. Patients included were adults with a first-time diagnosis of GD treated with ATD. Exclusion criteria included pregnancy and glucocorticoid treatment. The primary endpoint was failure to enter and sustain remission defined as relapse of hyperthyroidism within 12 months after ATD cessation, inability to stop ATD within 24 months, or radioiodine treatment or thyroidectomy. Two hundred seventy-eight patients were included in the study, and 4 patients withdrew consent. No adverse effects were found.
Results
Participants were aged 44 ± 14 years at enrollment and 79% were female. The risk of failure to enter and sustain remission was 42% [95% confidence interval (CI) 33-50%] in the vitamin D group and 32% [CI 24-40%] in the placebo group corresponding to a relative risk of 1.30 [CI 0.95-1.78].
Conclusions
Vitamin D supplementation did not improve the treatment of GD in patients with normal or insufficient vitamin D status. Thus, supplementation with high-dose vitamin D cannot be recommended for GD. Study registration: ClinicalTrials.gov NCT02384668.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus N, Denmark.
- Department of Internal Medicine, Herlev Hospital, Herlev, Hovedstaden, Denmark.
- Medical Department, Regionshospitalet Horsens, Horsens, Midtjylland, Denmark.
- Medical Department, Aalborg University Hospital, Aalborg, North Denmark Region, Denmark.
- Department of Internal Medicine, Regional Hospital Randers, Randers, Denmark.
- Medical Department, Gødstrup Regional Hospital, Herning, Denmark.
ORCID-Profile: Diana Grove-Laugesen, Eva Ebbehoj, Torquil Watt, Torben Østergård, Bjarke Johannessen Bruun, Jens Juel Christiansen, Klavs Würgler Hansen, Lars Rejnmark
Zitieren
APA
Grove-Laugesen, D., Ebbehoj, E., Watt, T., Riis, A. L., Østergård, T., Bruun, B. J., Juel Christiansen, J., Hansen, K. W., & Rejnmark, L. (2023). Effect of Vitamin D Supplementation on Graves' Disease: The DAGMAR Trial. Thyroid®. https://doi.org/10.1089/thy.2023.0111
Vancouver
Grove-Laugesen D, Ebbehoj E, Watt T, Riis AL, Østergård T, Bruun BJ, et al. Effect of Vitamin D Supplementation on Graves' Disease: The DAGMAR Trial. Thyroid®. 2023. doi:10.1089/thy.2023.0111
BibTeX
@article{GroveLaugesen2023,
author = {Grove-Laugesen, Diana and Ebbehoj, Eva and Watt, Torquil and Riis, Anne Lene and Østergård, Torben and Bruun, Bjarke Johannessen and Juel Christiansen, Jens and Hansen, Klavs Würgler and Rejnmark, Lars},
title = {Effect of Vitamin D Supplementation on Graves' Disease: The DAGMAR Trial},
journal = {Thyroid®},
year = {2023},
doi = {10.1089/thy.2023.0111}
}
EUVIMED